Drug Trial Radar · NCT04566380
ONO-4538 Phase II Rollover Study (ONO-4538-98)
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Sep 10, 2020
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 28, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is intended to confirm the long-term safety of ONO-4538 in pan-tumor participants being treated with ONO-4538 monotherapy or in Combination with Other Therapies in clinical trials.
Conditions
- Pan-tumor
Interventions
ONO-4538Drug
IV infusion over 30 minutes
oxaliplatinDrug
IV infusion over 2 hours
S-1Drug
Administered orally twice daily
capecitabineDrug
Administered orally twice daily
bevacizumabDrug
IV infusion over 30 minutes
temozolomideDrug
Administered orally once daily for 5 days every 28 days
IpilimumabDrug
IV infusion over 30 minutes
ONO-7703Drug
Administered orally twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (Aes)Time frame: From Day 1 up to 28 days after the end of the treatment phase
Locations
44 sites in 3 countries. Site status is shown where the registry gives one.
Chiba Clinical Site2
Chiba, Chiba, Japan · Completed
Chiba Clinical Site1
Kashiwa, Chiba, Japan · Completed
Ehime Clinical Site1
Matsuyama, Ehime, Japan · Completed
Fukuoka Clinical Site2
Fukuoka, Fukuoka, Japan · Completed
Fukuoka Clinical Site3
Fukuoka, Fukuoka, Japan · Completed
Fukuoka Clinical Site1
Kurume, Fukuoka, Japan · Completed
Hiroshima Clinical Site1
Hiroshima, Hiroshima, Japan · Recruiting
Hokkaido Clinical Site1
Sapporo, Hokkaido, Japan · Recruiting
Hyogo Clinical Site1
Akashi, Hyōgo, Japan · Completed
Kanagawa Clinical Site1
Yokohama, Kanagawa, Japan · Completed
Kyoto Clinical Site1
Kyoto, Kyoto, Japan · Recruiting
Oita Clinical Site1
Yufu, Oita Prefecture, Japan · Recruiting
Okayama Clinical Site1
Okayama, Okayama-ken, Japan · Recruiting
Osaka Clinical Site2
Osaka, Osaka, Japan · Recruiting
Osaka Clinical Site1
Suita, Osaka, Japan · Recruiting
Osaka Clinical Site3
Takatsuki, Osaka, Japan · Recruiting
Saitama Clinical Site1
Hidaka, Saitama, Japan · Recruiting
Saitama Clinical Site2
Kitaadachi-gun, Saitama, Japan · Completed
Tokyo Clinical Site3
Bunkyo-ku, Tokyo, Japan · Recruiting
Tokyo Clinical Site2
Chuo-ku, Tokyo, Japan · Recruiting
Tokyo Clinical Site1
Koto-ku, Tokyo, Japan · Completed
Tokyo Clinical Site5
Koto-Ku, Tokyo, Japan · Recruiting
Tokyo Clinical Site4
Shinjuku-ku, Tokyo, Japan · Recruiting
Daegu Clinical Site2
Daegu, South Korea · Recruiting
Daegu Clinical Site3
Daegu, South Korea · Recruiting
Gyeonggi-do Clinical site1
Gyeonggi-do, South Korea · Recruiting
Hwasun Clinical Site1
Hwasun, South Korea · Recruiting
Incheon Clinical Site1
Incheon, South Korea · Completed
Seoul Clinical Site1
Seoul, South Korea · Recruiting
Seoul Clinical Site2
Seoul, South Korea · Completed
Seoul Clinical Site3
Seoul, South Korea · Recruiting
Seoul Clinical Site4
Seoul, South Korea · Recruiting
Seoul Clinical Site5
Seoul, South Korea · Recruiting
Seoul Clinical Site6
Seoul, South Korea · Recruiting
Suwon Clinical Site1
Suwon, South Korea · Recruiting
Daegu Clinical Site1
Daegu, South Korea, South Korea · Recruiting
Kaohsiung Clinical Site1
Kaohsiung City, Taiwan · Completed
Kaohsiung Clinical Site2
Kaohsiung City, Taiwan · Completed
New Taipei City Clinical Site1
New Taipei City, Taiwan · Recruiting
Tainan Clinical Site1
Tainan, Taiwan · Recruiting
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.